Cytochrome P450 isoforms 1A1, 1B1 AND 2W1 as targets for therapeutic intervention in head and neck cancer - Presa, Daniela; Khurram, Syed A.; Zubir, Amir Z. A.; Smarakan, Sneha; Cooper, Patricia A.; Morais, Goreti R.; Sadiq, Maria; Sutherland, Mark; Loadman, Paul M.; McCaul, James; Shnyder, Steven D.; Patterson, Laurence H.; et al. (Scientific reports, 2021)
Keywords: 631/154; 631/67; Animals; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Carcinogens; Cell Line, Tumor; Cohort Studies; Cytochrome; Cytochrome P-450 CYP1A1 - antagonists & inhibitors; Cytochrome P-450 CYP1A1 - metabolism; Cytochrome P-450 CYP1B1 - antagonists & inhibitors; Cytochrome P-450 CYP1B1 - metabolism; Cytochrome P450; Cytochrome P450 Family 2 - antagonists & inhibitors; Cytochrome P450 Family 2 - metabolism; Epidemiology; Female; Head & neck cancer; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - pathology; Heterocyclic Compounds, 3-Ring - pharmacology; Heterocyclic Compounds, 3-Ring - therapeutic use; Humanities and Social Sciences; Humans; Indoles - pharmacology; Indoles - therapeutic use; Isoforms; Metabolic activation; Metabolic rate; Mice; multidisciplinary; Prodrugs; Prodrugs - pharmacology; Prodrugs - therapeutic use; Pyrroles - pharmacology; Pyrroles - therapeutic use; Science; Science (multidisciplinary); Tumors; Xenograft Model Antitumor Assays; Xenografts; United States--US; Detroit Michigan